Skip to main content
SpringerLink
Log in

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Beyls C, et al. Lopinavir-ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia. Circulation: Arrhythmia and Electrophysiology : 9 Jul 2020. Available from: URL: https://doi.org/10.1161/CIRCEP.120.008798

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients. Reactions Weekly 1814, 9 (2020). https://doi.org/10.1007/s40278-020-80996-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-80996-7

Search

Navigation